Publications by authors named "Bianca Zingano"
Article Synopsis
- The study aimed to adapt the Faux Pas Recognition Test (FPRT) into Brazilian Portuguese and assess its effectiveness in evaluating Theory of Mind impairment in neuropsychiatric disorders.
- A multicentric study involved 153 healthy participants and used various psychometric analyses, including regression and factor analysis, to understand the relationship between FPRT scores and factors like age and education.
- The results indicated good internal consistency of the FPRT, with a positive correlation between test scores and education/social class, making it suitable for diverse educational contexts in Brazil.
Hospital Anxiety and Depression Scale-Anxiety subscale (HADS-A) and The State-Trait Anxiety Inventory (STAI) accuracy for anxiety disorders detection in drug-resistant mesial temporal lobe epilepsy patients.
J Affect Disord
March 2019
Background: Mesial temporal lobe epilepsy with hippocampal sclerosis (MTLE-HS) is the most prevalent type of surgically remediable epilepsy and highly associated with psychiatric comorbidities. This study aimed to evaluate Hospital anxiety and depression scale-anxiety subscale (HADS-A) and The State-Trait Anxiety Inventory - Trait subscale (STAI-T) accuracy for detection of anxiety disorders in patients with drug-resistant MTLE-HS.
Methods: One hundred three consecutive patients with drug-resistant MTLE-HS were enrolled.
Depression is relatively common among patients with epilepsy, but often with predominant atypical symptoms. Some antiepileptic drugs show positive psychotropic effects, but these are not always sufficient to stabilize mood in epilepsy patients. Antidepressants are recommended to treat atypical depression but are not always effective and present a certain risk of seizure provocation.
View Article and Find Full Text PDFBackground: Inflammation and oxidative stress (OS) are risk factors for cardiovascular disease in chronic kidney disease (CKD). This study assessed the acute effect of simvastatin on inflammatory and OS markers in stage 3 and 4 CKD patients.
Methods: Randomized, placebo-controlled, double-blind, cross-over study comprising 66 patients who were randomized to simvastatin (20 mg/day) or placebo for two 8-week periods.